Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Enbrel cost $350 mil.

Executive Summary

Immunex estimates it cost $350 mil. to bring Enbrel (etanercept) to market. The investment could make future endeavors more efficient, CEO Ed Fritzky says Sept. 24. "Once you have researchers who understand rheumatology, you can leverage that with your next rheumatology molecule. But nevertheless, I don't think anyone should have the expectation where it's going to cost a lot less to move molecules through the pipeline"
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS038579

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel